SIOX — Sio Gene Therapies Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Tesla, Abiomed, Adaptimmune Therapeutics
Axovant: Up on positive data from gene therapy trial for Parkinson's disease
Brief: Axovant Announces Positive Data On Axo-Lenti-Pd
Brief: Axovant Gene Therapies Files For Proposed Mixed Shelf Offering Of Up To $750 Mln
U.S. STOCKS ON THE MOVE-BlackBerry, U.S. Steel, Carmax, CalAmp
U.S. RESEARCH ROUNDUP-Accenture, LyondellBasell Industries, Reata Pharmaceuticals
Brief: Axovant Provides Clinical Program Update For Axo-Aav-Gm1
Brief: Axovant Announces Amendment To Credit Facility With Hercules Capital
Brief: Axovant Gene Therapies Receives Orphan Drug Designation From FDA For AXO-AAV-GM1
Brief: Axovant Posts Q2 Loss Per Share $0.61
Axovant shares leap on promising gene therapy data
Brief: Axovant Presents First Evidence Of Clinical Stabilization In Tay-Sachs Disease At The European Society Of Gene And Cell Therapy 27th Annual Congress
U.S. STOCKS ON THE MOVE-Facebook, Beyond Meat, Lululemon, Mallinckrodt, Kellogg
Roivant family moves as Japanese pharma firm buys stake in co
U.S. STOCKS ON THE MOVE-Facebook, Beyond Meat, Lululemon, GrubHub, Kellogg
Axovant is not among subsidiaries referenced in Sumitomo-Roivant deal - Leerink
U.S. STOCKS ON THE MOVE-Facebook, Beyond Meat, GrubHub, Kellogg
Roivant family rises as Japanese pharma firm buys stake in firm
Gene therapy could have worldwide market of ~$21.6 trln - Guggenheim